Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: A retrospective analysis

CURRENT STATUS: UNDER REVIEW

BMC Pulmonary Medicine  BMC Series

Teppei Yamaguchi  yteppei@aichi-cc.jp
Aichi Cancer Center Hospital
Corresponding Author
ORCiD: 0000-0002-8909-5709

Junichi Shimizu
Aichi Cancer Center Hospital

Takaaki Hasegawa
Aichi Cancer Center Hospital

Yoshitsugu Horio
Aichi Cancer Center Hospital

Yoshitaka Inaba
Aichi Cancer Center Hospital

Nobuhiro Hanai
Aichi Cancer Center Hospital

Kei Muro
Aichi Cancer Center Hospital

Toyoaki Hida
Aichi Cancer Center Hospital

DOI: 10.21203/rs.2.18450/v1

SUBJECT AREAS  Pulmonology
KEYWORDS

Non-small cell lung cancer, head and neck cancer, gastric cancer, pneumonitis, nivolumab, PD-1
Abstract

Background

Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, has shown survival benefit in clinical trials of various malignant tumors. Nivolumab-induced pneumonitis is major immune-related adverse event (irAE) that is occasionally serious and life-threatening. The aim of this study was to examine the association between pre-existing interstitial lung disease (ILD) on chest computed tomography (CT) and nivolumab-induced pneumonitis among different types of solid tumors.

Methods

We retrospectively collected the clinical data of 311 patients who were diagnosed with non-small cell lung cancer (NSCLC), head and neck cancer (HNC), or gastric cancer (GC), and treated with nivolumab monotherapy. Patients who underwent chest CT immediately before starting nivolumab without previous thoracic radiotherapy or other immune checkpoint inhibitors were eligible. We collected baseline patient characteristics and assessed pre-existing ILD on baseline chest CT.

Results

Finally, 188 patients were included in the analysis: 96 patients with NSCLC, 43 patients with HNC, and 49 patients with GC. NSCLC patients had a significantly higher rate of pre-existing ILD compared with HNC/GC patients ($P=0.047$). Nivolumab-induced pneumonitis occurred in 11.7% (22 of 188), including 14.6% (14 of 96) of NSCLC, and 8.7% (8 of 92) of HNC/GC. Univariate and multivariate logistic regression analyses revealed that pre-existing ILD (odds ratio, 5.92; 95% confidence interval (CI), 2.07–18.54, $P=0.0008$) and male sex (odds ratio, 5.58; 95% CI, 1.01–104.40, $P=0.049$) significantly increased the risk of nivolumab-induced pneumonitis.
Conclusion

Our results indicated that pre-existing ILD and male sex are risk factors for nivolumab-induced pneumonitis in solid tumors.

Introduction

Nivolumab is a selective, fully humanized IgG4 monoclonal antibody that blocks binding between programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1)/PD-L2, encouraging the antitumor activity of T cells. Nivolumab has demonstrated antitumor efficacy in clinical trials of various malignant tumors, including melanoma, renal cell cancer, non-small-cell lung cancer (NSCLC), head and neck cancer (HNC), and gastric cancer (GC) [1–6]. However, immune checkpoint inhibitors (ICI) including nivolumab can induce immune-related adverse events (irAEs) such as skin rash, colitis, endocrine disorders, hepatotoxicity, and pneumonitis. Among them, pneumonitis is a relatively common but potentially life-threatening irAE. We recently reported that pre-existing interstitial lung diseases (ILD) is a risk factor for anti-PD-1-induced pneumonitis in patients with NSCLC; however, it is not clear if this tendency applies to other types of tumors [7]. Although the incidences of most irAEs are considered to be similar regardless of tumor type, in the case of pneumonitis these frequencies may differ across tumor types. In the previous phase III clinical trials of nivolumab, the incidence of nivolumab-induced pneumonitis was reported as 3.5–5% in NSCLC, 2.1% in SQ-HNC, and < 1% in GC, and thus it appears to vary among the different cancer types [2–5]. We speculated that these tumor-specific bias in the incidence of pneumonitis may be related to pre-existing ILD. Moreover, patients complicated with ILD are routinely excluded from clinical trials,
therefore, these questions need to be resolved by real-world data.

The aim of this study was to evaluate the association between ILD on chest computed tomography (CT) and nivolumab-induced pneumonitis among cohorts with different tumor types, including NSCLC, HNC, and GC.

Materials and methods

Patients

We retrospectively reviewed 311 patients who were diagnosed with NSCLC, HNC, or GC and treated with nivolumab monotherapy at Aichi Cancer Center Hospital, Japan between 17 December 2015 and 30 April 2018. Patients who underwent chest CT immediately before the start of nivolumab treatment were included in the analysis. Patients who received other chemotherapy regimens between the last chest CT and nivolumab and who previously received thoracic radiotherapy or any immune checkpoint inhibitors before nivolumab were excluded. All patients were treated with nivolumab monotherapy at 3 mg/kg every 2 weeks. The following data at the time of nivolumab initiation were collected from medical records: age, sex, smoking status, performance status, serum levels of C-reactive protein (CRP), serum levels of lactate dehydrogenase (LDH), chest CT before nivolumab, number of treatment cycles of nivolumab, and date and severity of nivolumab-induced pneumonitis. This study was approved by the institutional review board of the Aichi Cancer Center Hospital (No. 2018-1-046).

Radiographic analysis

All patients in our study were examined with a helical CT scanner with a slice thickness of 1–10 mm (mostly 5 mm). Pre-existing ILD on baseline chest CT was assessed according to the American Thoracic Society (ATS)/European Respiratory
Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) CT criteria for usual interstitial pneumonia (UIP) by two diagnostic radiologists (T. H. and Y. I.) [8]. The clinical data were blinded, and cases of discrepancy were resolved by consensus. The diagnosis of nivolumab-induced pneumonitis was confirmed by two pulmonologists (T. Y. and J. S.) according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.0, with reference to careful examination to exclude other pulmonary diseases such as infection, cancer progression, congestive heart failure, and pulmonary embolus [9].

**Statistical analysis**

Differences in characteristics between the two cohorts were evaluated using the Chi-square test to compare categorical variables and Mann-Whitney U test to compare continuous variables. Univariate and multivariate logistic regression analyses were conducted to assess the potential independent risk factors for pneumonitis associated with nivolumab. All variables with $P$-values <0.1 in the univariate analysis were entered into the multivariate analyses. All tests were two-sided with a significance level of $P<0.05$. All analyses were preformed using JMP version 11.0 statistical software (SAS Institute Inc., Cary, NC, USA). The analysis cut-off date was 31 July 2018.

**Results**

**Patient characteristics**

We screened 311 consecutive patients with solid tumors who received nivolumab and excluded 123 patients: 62 patients with no chest CT prior to nivolumab, 57 patients who previously received thoracic RT, and four patients who previously received atezolizumab. Finally, 188 patients were analyzed in our study, including
96 patients with NSCLC, 43 patients with HNC, and 49 patients with GC (Figure 1). Patient characteristics of the NSCLC group and the HNC/GC group are summarized in Table 1 and Supplemental Table 1. No significant differences were detected in age, sex, smoking status, performance status, and number of treatment cycles of nivolumab between the NSCLC group and the HNC/GC group. In the analysis of pre-existing ILD on chest CT, the NSCLC group had a significantly higher rate of pre-existing ILD compared to the HNC / GC group (P = 0.047). The majority of patients were classified as “non-fibrosis”, however, 26 patients (27.1%) in the NSCLC group and 14 patients (15.2%) in the HNC/GC group had ILD on chest CT. Based on the ATS/ERS/JRS/ALAT CT criteria for UIP, 17 patients (17.7%) were classified as inconsistent with UIP, three (3.1%) as possible UIP, and six (6.3%) as UIP in the NSCLC group, while in the HNC/GC group, 11 (12.0%) patients were classified as inconsistent with UIP, one (1.1%) as possible UIP, and two (2.2%) as UIP. In addition, pre-existing ILD was predominant in male patients, accounting for 38 of 133 patients (28.6%). While in females, only two of 55 patients (3.6%) had pre-existing ILD and were classified as “inconsistent with UIP.”

**Incidence of nivolumab-induced pneumonitis and UIP diagnosis categories**

Incidence of nivolumab-induced pneumonitis according to UIP diagnosis categories are listed in Table 2. The overall nivolumab-induced pneumonitis occurrence rate was 11.7% (22 of 188) and the grade 3 or higher pneumonitis rate was 1.6% (3 of 188). In an analysis based on tumor type, nivolumab-induced pneumonitis occurred in 14.6% (14 of 96) of the NSCLC group, and in 8.7% (eight of 92) of the HNC/GC group. The median time to onset of pneumonitis from starting nivolumab was 63 days (range, 6–634 days) in the NSCLC group and 56 days (range, 2–107 days) in the HNC/GC group. In cases with no fibrosis, pneumonitis occurred in 5.4% (eight of
148 patients), including 5.7% (four of 70) of NSCLC and 5.1% (four of 78) of HNC/GC. Whereas in cases with pre-existing ILD, pneumonitis complicated 35.0% (14 of 40 patients), including 38.5% (10 of 26 patients) of NSCLC and 28.6% (four of 14 patients) of HNC/GC. According to an analysis of the ATS/ERS/JRS/ALAT CT criteria for UIP, pneumonitis was observed in 32.1% (nine of 28) patients with “inconsistent with UIP” and in 41.7% (five of 12) with “possible UIP/UIP.” Grade 3 or higher pneumonitis developed only in cases with pre-existing ILD, two cases of grade 3 were in NSCLC with inconsistent with UIP and UIP, and another case of grade 5 was HNC with possible UIP.

Subsequently, we performed univariate and multivariate logistic regression analyses to evaluate risk factors for nivolumab-induced pneumonitis. In the multivariate analysis, pre-existing ILD (odds ratio, 5.92; 95% confidence interval (CI), 2.07-18.54; \( P=0.0008 \)) and male sex (odds ratio, 5.58; 95% CI, 1.01-104.40; \( P=0.049 \)) were significant independent predictive factors for nivolumab-induced pneumonitis (Table 3).

Discussion

In this study, the overall incidence of all-grade pneumonitis was 11.7%, similar to a previous retrospective Japanese cohort study in patients with NSCLC treated by nivolumab [10-11]. Although there was no significant difference in the univariate analysis, the NSCLC group tended to have a higher incidence of pneumonitis (14.6%) compared with the HNC/GC group (8.7%), which was related to the high trend of complicating pre-existing ILD in the NSCLC group (\( P=0.047 \)).

The present analysis revealed that pre-existing ILD and male sex were significant independent risk factors for nivolumab-induced pneumonitis in patients with solid
tumors. Previous evidence has strongly indicated that pre-existing ILD is a risk factor for chemotherapy-induced pneumonitis, and these reports were particularly prevalent in lung cancer [12–17]. These findings are related to the fact that both lung cancer and ILD are closely associated with cigarette smoking. There is substantial epidemiological evidence that patients with ILD have a high risk of lung cancer [18, 19], whereas it has been reported that 10%–20% of patients were complicated with ILD when lung cancer was diagnosed [13, 20]. We previously reported that pre-existing ILD is a risk factor for anti-PD-1-induced pneumonitis [7]. However, it has not been elucidated whether pre-existing ILD is at risk of pneumonitis when using anti-PD-1 agents for other type of tumors. In previous phase III clinical trials, HNC and GC had a lower incidence of nivolumab-induced pneumonitis compared with NSCLC. While a recent meta-analysis indicated that anti-PD-1-related pneumonitis of all grades develops more frequently in NSCLC and renal cell cancer than in melanoma [21, 22].

In our analysis based on pre-existing ILD on chest CT, NSCLC and HNC/GC showed similar trends in the development of pneumonitis. Interestingly, in patients with no fibrosis, the incidence of nivolumab-induced pneumonitis was approximately 5% in both NSCLC and HNC/GC, similar to results reported in previous large clinical trials. Moreover, in patients with pre-existing ILD, the incidence of nivolumab-induced pneumonitis jumped to approximately 30%. However, most cases of pneumonitis associated with nivolumab are relatively mild and classified as grade 1 to 2. It has been reported that nivolumab-induced pneumonitis responds well to steroid therapy and its mortality rate is low compared with gefitinib-induced pneumonitis, which is characterized by rapid progression and a high mortality rate of around 30% to 40% [23].
It should be emphasized that increased risk of anti-PD-1-induced pneumonitis is not synonymous with the avoidance of anti-PD-1 treatment. Previous studies have demonstrated that the development of irAEs is associated with clinical benefit of ICIs in melanoma and NSCLC [24–29]. In a recent retrospective cohort study in patients with NSCLC treated with nivolumab (n=613), landmark analyses of PFS at 2 months revealed no significant differences in PFS between patients with or without pneumonitis (7.9 vs. 5.9 months; \( P = 0.872 \)). Moreover, in our previous report, patients with anti-PD-1-induced pneumonitis had relatively favorable survival outcomes [7]. ICI-induced pneumonitis may not lead to poor outcomes, unlike pneumonitis with a cytotoxic chemotherapy or molecularly targeted therapy that has been reported to have a poor prognosis [30]. Therefore, indications for ICI treatment should be judged comprehensively, taking into consideration pre-existing ILD as well as pulmonary function, which affects the severity of pneumonitis. A history of thoracic radiotherapy would also affect the incidence of chemotherapy-related pneumonitis in patients with NSCLC. Tamiya et al. reported that the incidence of nivolumab-induced pneumonitis was significantly higher in a group with thoracic radiation history than in a group without thoracic radiation history [10]. A higher incidence of nivolumab-induced pneumonitis in patients with thoracic radiation history may be because nivolumab can induce radiation recall pneumonitis. Therefore, our analysis excluded patients with a history of thoracic radiation to prevent bias.

Male sex was also detected as a risk factor for nivolumab-induced pneumonitis. In a retrospective analysis of gefitinib, not only pre-existing ILD but also male sex and a history of smoking were significantly associated with developing gefitinib-induced pneumonitis [31]. On the other hand, our analysis showed that only two out of 55
female patients (3.6%) had pre-existing ILD and these two patients were classified as "inconsistent with UIP." Therefore, to investigate the relationship between pre-existing ILD and nivolumab-induced pneumonitis particularly in females, further validation of another cohort is needed.

There are several limitations in the present study. First, this was a single-site retrospective study that used chart reviews of a relatively small patient cohort. Second, the number of patients with HNC/GC was smaller, since nivolumab was approved earlier for NSCLC than HNC/GC. Third, we excluded patients who previously received thoracic radiation or other ICIs to prevent biases; however, since the standard treatment differs for each cancer type it is possible that the effects of prior treatment could not be completely excluded. Fourth, the patient cohort was across multiple cancer types, which prevented cancer-specific survival analysis.

Conclusions

Our findings showed that pre-existing ILD is a common risk factor for nivolumab-induced pneumonitis in solid cancer treatment, including NSCLC, HNC, and GC. The difference in the incidence of anti-PD-1-induced pneumonitis across various tumor types seems to have occurred due to the difference in the pre-existing ILD complication rate. To investigate the association between nivolumab-induced pneumonitis and pre-existing ILD across whole tumors, further analyses in a larger multicenter collaborative study are required. Likewise, further investigations are also required for anti-PD-L1-antibodies and chemo-ICI combination therapies to examine the relationship between pre-existing ILD and ICI-induced pneumonitis.
Abbreviations

ILD, interstitial lung disease; NSCLC, non-small cell lung cancer; PD-1, programmed death 1; PD-L1, programmed death ligand-1; HNC, head and neck cancer; GC, gastric cancer; ICI, immune check point inhibitors; irAE, immune-related adverse events; CT, computed tomography; UIP, usual interstitial pneumonia; CRP, C-reactive protein; LDH, serum levels of lactate dehydrogenase; CI, confidence interval.

Declarations

Acknowledgments

We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

Dr. Hida has obtained research grants from Ono Pharmaceutical, Novartis Pharma, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, Pfizer, Bristol-Meyers Squibb, Clovis Oncology, Eisai, Takeda Bio, Sumitomo Dainippon Pharma, Abbvie, Merck Serono, MSD, Kyowa Hakko Kirin, Daiichi Sankyo, and Astellas, and has received personal fees from Ono Pharmaceutical, Novartis Pharma, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, Pfizer, Clovis Oncology, and Bristol-Meyers Squibb. All other authors have no conflicts of interest. Dr. Muro
has obtained research grants from Ono Pharmaceutical.

References

1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.

2. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123-35.

3. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627–39.

4. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856–67.

5. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.

6. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1803-13.

7. Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in
patients with non-small cell lung cancer: A retrospective analysis. Lung Cancer. 2018;125:212-7.

8. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

9. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010). U.S. Department of Health and Human Services, National Institute of Health National Cancer Institute. Available at https://www.be/services/doCAE_c/ctc/CT4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on July 12, 2019)

10. Tamiya A, Tamiya M, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, et al. Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pretreated Advanced Non-small Cell Lung Cancer. Anticancer Res. 2017;37:5199-205.

11. Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, et al. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer. 2018;119:14-20.

12. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008;177:1348-57.

13. Niho S, Goto K, Yoh K, Kim YH, Ohmatsu H, Kubota K, et al. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by
chemotherapeutic drugs. Jpn J Clin Oncol 2006;36:269–73.

14. Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K, Homma S. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology. 2010;15:88–92.

15. Minegishi Y, Takenaka K, Mizutani H, Sudoh J, Noro R, Okano T, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med. 2009;48:665–72.

16. Chen YJ, Chen LX, Han MX, Zhang TS, ZhouZR, Zhong DS. The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review. Medicine (Baltimore). 2015;94:e1451.

17. Koyama N, Katayanagi S, Kawachi S. Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: The impact of usual interstitial pneumonia. PLoS One. 2018;13:e0198886.

18. Archontogeorgis K, Steiropoulos P, Tzouvelekis A, Nena E, Bouros D. Lung cancer and interstitial lung diseases: a systematic review. Pulm Med. 2012;2012:315918.

19. Bouros D, Hatzakis K, Labrakis H, Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest. 2002;121:1278–89.

20. Omori T, Tajiri M, Baba T, Ogura T, Iwasawa T, Okudela K, et al. Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia. Ann Thorac Surg. 2015;100:954–60.
21. Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, et al. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730.

22. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016;2:1607-16.

23. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008;177:1348–57.

24. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151:1206–12.

25. Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol. 2016;44:117–22.

26. Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152:45–51.

27. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22:886–94.

28. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al.
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33:773–81.

29. Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2018;4:374–8.

30. Fujimoto, R. Kato, T. Morimoto, R. Shimizu, Y. Sato, M. Kogo, J. et al. Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. PLoS One. 2016;11:e0168465.

31. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549–56.

Tables
### Table 1. Patient characteristics

| Characteristics                          | NSCLC n=96   | HNC/GC n=92  |
|------------------------------------------|--------------|--------------|
| **Age, years**                           |              |              |
| Median (range)                           | 68 (44–80)   | 67 (24–85)   |
| <65                                      | 33 (34.4)    | 38 (41.3)    |
| ≥65                                      | 63 (65.6)    | 54 (58.7)    |
| **Sex**                                  |              |              |
| Male                                     | 68 (70.8)    | 65 (70.7)    |
| Female                                   | 28 (29.2)    | 27 (29.3)    |
| **Smoking status**                       |              |              |
| Current/ex-smoker                        | 74 (77.1)    | 67 (72.8)    |
| Never-smoker                             | 22 (22.9)    | 25 (27.2)    |
| **Performance status**                   |              |              |
| 0–1                                      | 82 (85.4)    | 74 (80.4)    |
| ≥2                                       | 14 (14.6)    | 18 (19.6)    |
| **No. of treatment cycles of nivolumab** |              |              |
| Median (range)                           | 5 (1–58)     | 5 (1–25)     |
| **Pre-existing ILD on chest CT**         |              |              |
| Normal                                   | 70 (72.9)    | 78 (84.8)    |
| Pre-existing ILD                         | 26 (27.1)    | 14 (15.2)    |
| UIP                                      | 6 (6.3)      | 2 (2.2)      |
| Possible UIP                             | 3 (3.1)      | 1 (1.1)      |
| Inconsistent with UIP                    | 17 (17.7)    | 11 (12.0)    |

NSCLC, non-small cell lung cancer; HNC, head and neck cancer; GC, gastric cancer; Adeno, adenocarcinoma; Sq, squamous cell carcinoma; ILD, interstitial lung disease; UIP, usual interstitial pneumonia
| Diagnosis Category                                      | Total, n | Any grade, n (%) |
|--------------------------------------------------------|----------|------------------|
| Total                                                  | 188      | 22 (11.7)        |
| NSCLC                                                  | 96       | 14 (14.6)        |
| HNC / GC                                               | 92       | 8 (8.7)          |
| No fibrosis, all tumor types                           | 148      | 8 (5.4)          |
| No fibrosis, NSCLC                                     | 70       | 4 (5.7)          |
| No fibrosis, HNC/GC                                    | 78       | 4 (5.1)          |
| Pre-existing ILD, all tumor types                      | 40       | 14 (35.0)        |
| Inconsistent with UIP, all tumor types                  | 28       | 9 (32.1)         |
| Pre-existing ILD, NSCLC                                | 26       | 10 (38.5)        |
| Inconsistent with UIP, NSCLC                           | 17       | 6 (35.3)         |
| Possible UIP/UIP, NSCLC                                | 9        | 4 (44.4)         |
| Pre-existing ILD, HNC/GC                               | 14       | 4 (28.6)         |
| Inconsistent with UIP, HNC/GC                          | 11       | 3 (27.3)         |
| Possible UIP / UIP, HNC/GC                             | 3        | 1 (33.3)         |

NSCLC, non-small cell lung cancer; HNC, head and neck cancer; GC, gastric cancer; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; * case of HNC with possible UIP had grade 5 pneumonitis.
Table 3. Risk factors for nivolumab-induced pneumonitis in patients with solid tumors by univariate and multivariate logistic regression analysis

| Risk Factor                  | Univariate model | Multivariate model |
|------------------------------|------------------|--------------------|
|                              | OR (95% CI)      | P-value            | OR      |
| Age, years                   |                  |                    |         |
| ≥65 vs. <65                  | 3.05 (1.08–10.90)| 0.034              | 1.53    |
| Sex                          |                  |                    |         |
| Male vs. female              | 10.13 (2.03–183.77)| 0.0018            | 5.58    |
| Smoking status               |                  |                    |         |
| Current/ex-smoker vs. Never-smoker | 1.57 (0.55–5.67) | 0.42              |         |
| Performance status           |                  |                    |         |
| ≥2 vs. 0 or 1                | 0.75 (0.17–2.38) | 0.64              |         |
| Tumor types                  |                  |                    |         |
| NSCLC vs. HNC/GC             | 1.79 (0.73–4.70) | 0.21              |         |
| Pre-existing ILD             |                  |                    |         |
| Yes vs. No                   | 9.42 (3.67–25.80)| <0.0001           | 5.92    |
| LDH (IU/l)                   |                  |                    |         |
| ≥240 vs. <240                | 0.58 (0.11–2.42) | 0.47              |         |
| CRP (mg/dl)                  |                  |                    |         |
| ≥1 vs. <1                    | 0.97 (0.24–3.66) | 0.96              |         |

Sq, squamous cell carcinoma; ILD, interstitial lung disease; LDH, lactate dehydrogenase; CRP, C-reactive protein; OR, odds ratio; CI, confidence interval.

Figures
Figure 1

Patient flowchart. NSCLC, non-small cell lung cancer; HNC, head and neck cancer;

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

NIVO_NSCLC_HNC_GC_supple_table.docx